BRPI0409471A - processo para a preparação de 2-cianopirrolidinas n-substituìdas - Google Patents
processo para a preparação de 2-cianopirrolidinas n-substituìdasInfo
- Publication number
- BRPI0409471A BRPI0409471A BRPI0409471-9A BRPI0409471A BRPI0409471A BR PI0409471 A BRPI0409471 A BR PI0409471A BR PI0409471 A BRPI0409471 A BR PI0409471A BR PI0409471 A BRPI0409471 A BR PI0409471A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- reacting
- preparation
- halogen
- substituted
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical class N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 239000012024 dehydrating agents Substances 0.000 abstract 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"PROCESSO PARA A PREPARAçãO DE 2-CIANOPIRROLIDINAS N-SUBSTITUìDAS". A presente invenção refere-se a um processo para a preparação de uma N-(glicil N<39>-substituído)-2-cianopirrolidina compreendendo pelo menos (a) reagir, na presença de dimetilformamida, um composto de fórmula (V) em que, independentemente um do outro, X~ 1~ e X~ 3~ são halogênio; X~ 2~ é halogênio, OH, O-C(=O)-CH~ 2~X~ 3~, -O-SO~ 2~-alquila (C~ 1-8~) OU -O-SO~ 2~-(arila), com L-prolinamida, seguido por (b) reagir o composto resultante sem isolamento com um agente de desidratação, opcionalmente seguido por (c) reagir, na presença de uma base, o composto resultante sem isolamento com uma amina apropriada e (d) recuperar o composto resultante na forma livre ou na forma de sal de adição de ácido.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0308854A GB0308854D0 (en) | 2003-04-16 | 2003-04-16 | Organic compounds |
| GB0311836A GB0311836D0 (en) | 2003-05-22 | 2003-05-22 | Process for the manufacture of organic compounds |
| PCT/EP2004/003980 WO2004092127A1 (en) | 2003-04-16 | 2004-04-15 | Process for the preparation of n-substituted 2-cyanopyrrolidines |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0409471A true BRPI0409471A (pt) | 2006-05-02 |
| BRPI0409471B1 BRPI0409471B1 (pt) | 2015-11-03 |
| BRPI0409471B8 BRPI0409471B8 (pt) | 2021-05-25 |
Family
ID=33301223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0409471A BRPI0409471B8 (pt) | 2003-04-16 | 2004-04-15 | processo para preparação de 2-cianopirrolidinas n-substituídas |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US7375238B2 (pt) |
| EP (1) | EP1620396B1 (pt) |
| JP (1) | JP4672647B2 (pt) |
| KR (1) | KR101192538B1 (pt) |
| AR (1) | AR044019A1 (pt) |
| AU (2) | AU2004230245B2 (pt) |
| BR (1) | BRPI0409471B8 (pt) |
| CA (1) | CA2520128C (pt) |
| CL (1) | CL2004000804A1 (pt) |
| CO (1) | CO5700735A2 (pt) |
| CY (1) | CY1116008T1 (pt) |
| DK (1) | DK1620396T3 (pt) |
| EC (1) | ECSP056093A (pt) |
| ES (1) | ES2531084T3 (pt) |
| HR (1) | HRP20150163T1 (pt) |
| IL (1) | IL170887A (pt) |
| IS (1) | IS2979B (pt) |
| MA (1) | MA27765A1 (pt) |
| MX (1) | MXPA05011073A (pt) |
| MY (1) | MY139476A (pt) |
| NO (1) | NO333251B1 (pt) |
| NZ (1) | NZ542899A (pt) |
| PE (2) | PE20081293A1 (pt) |
| PL (1) | PL1620396T3 (pt) |
| PT (1) | PT1620396E (pt) |
| RU (1) | RU2369598C2 (pt) |
| SG (1) | SG160212A1 (pt) |
| SI (1) | SI1620396T1 (pt) |
| TW (1) | TWI359135B (pt) |
| WO (1) | WO2004092127A1 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20081293A1 (es) | 2003-04-16 | 2008-11-04 | Novartis Ag | Procedimiento de preparacion de compuestos 2(s)-cianopirrolidina n-(n'-glicilo sustituida) |
| DK3366283T3 (da) | 2004-01-20 | 2021-11-22 | Novartis Ag | Direkte sammenpresningsformulering og fremgangsmåde |
| GT200600008A (es) | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| EP1888562B1 (en) | 2005-04-22 | 2014-06-18 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| US20080279932A1 (en) * | 2005-08-04 | 2008-11-13 | Jean-Louis Reber | Compounds |
| WO2008066083A1 (fr) * | 2006-11-29 | 2008-06-05 | Mitsubishi Tanabe Pharma Corporation | Procédé de production d'un dérivé de n-(n'-glycyle substitué)-2-cyanopyrrolidine |
| WO2008084383A2 (en) * | 2007-01-10 | 2008-07-17 | Medichem, S.A. | Process for preparing vildagliptin |
| CZ2008512A3 (cs) | 2008-08-26 | 2010-03-10 | Zentiva, A. S | Zpusob prípravy vysoce cistého vildagliptinu |
| EA034049B1 (ru) * | 2009-07-31 | 2019-12-23 | КРКА, д.д., НОВО МЕСТО | Гранулят, включающий вилдаглиптин, способ его получения и фармацевтическая композиция |
| HUP0900638A2 (en) | 2009-10-07 | 2011-05-30 | Egyt Gyogyszervegyeszeti Gyar | Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions |
| IT1400714B1 (it) | 2010-07-06 | 2013-06-28 | Chemelectiva S R L | Processo ed intermedi per la preparazione di un principio attivo. |
| HU231050B1 (hu) | 2010-08-19 | 2020-02-28 | Egis Gyógyszergyár Nyrt. | Eljárás gyógyszerhatóanyag előállítására |
| ITMI20112224A1 (it) | 2011-12-06 | 2013-06-07 | Chemelectiva S R L | Nuovo processo ed intermedi per la sintesi di vildagliptin |
| WO2013179300A2 (en) * | 2012-05-04 | 2013-12-05 | Megafine Pharma (P) Ltd. | A process for the preparation of vildagliptin and its intermediate thereof |
| CN103922986B (zh) * | 2013-01-16 | 2017-02-15 | 上海彩迩文生化科技有限公司 | 维大列汀及其类似物、中间体及其制备方法和应用 |
| WO2015145467A1 (en) * | 2014-03-28 | 2015-10-01 | Laurus Labs Private Limited | An improved process for preparing vildagliptin |
| WO2021234430A1 (en) | 2020-05-17 | 2021-11-25 | Lotus International Pte. Ltd. | Modified release dosage form comprising vildagliptin and process for manufacturing the same |
| WO2022003405A1 (en) | 2020-07-03 | 2022-01-06 | Savoi Guilherme | One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510369A (en) * | 1994-07-22 | 1996-04-23 | Merck & Co., Inc. | Pyrrolidine thrombin inhibitors |
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6380398B2 (en) * | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| JP2003520849A (ja) * | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン |
| TW583185B (en) * | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
| JP2002265439A (ja) * | 2001-03-08 | 2002-09-18 | Mitsubishi Pharma Corp | シアノピロリジン誘導体およびその医薬用途 |
| PE20081293A1 (es) | 2003-04-16 | 2008-11-04 | Novartis Ag | Procedimiento de preparacion de compuestos 2(s)-cianopirrolidina n-(n'-glicilo sustituida) |
-
2004
- 2004-04-14 PE PE2007000421A patent/PE20081293A1/es not_active Application Discontinuation
- 2004-04-14 AR ARP040101251A patent/AR044019A1/es not_active Application Discontinuation
- 2004-04-14 PE PE2004000370A patent/PE20050021A1/es not_active Application Discontinuation
- 2004-04-15 PT PT04727557T patent/PT1620396E/pt unknown
- 2004-04-15 AU AU2004230245A patent/AU2004230245B2/en not_active Ceased
- 2004-04-15 MX MXPA05011073A patent/MXPA05011073A/es active IP Right Grant
- 2004-04-15 ES ES04727557T patent/ES2531084T3/es not_active Expired - Lifetime
- 2004-04-15 RU RU2005135331/04A patent/RU2369598C2/ru active
- 2004-04-15 SG SG200716949-3A patent/SG160212A1/en unknown
- 2004-04-15 NZ NZ542899A patent/NZ542899A/en not_active IP Right Cessation
- 2004-04-15 KR KR1020057019568A patent/KR101192538B1/ko not_active Expired - Fee Related
- 2004-04-15 WO PCT/EP2004/003980 patent/WO2004092127A1/en not_active Ceased
- 2004-04-15 PL PL04727557T patent/PL1620396T3/pl unknown
- 2004-04-15 US US10/552,835 patent/US7375238B2/en not_active Expired - Fee Related
- 2004-04-15 DK DK04727557.3T patent/DK1620396T3/en active
- 2004-04-15 CA CA2520128A patent/CA2520128C/en not_active Expired - Fee Related
- 2004-04-15 CL CL200400804A patent/CL2004000804A1/es unknown
- 2004-04-15 MY MYPI20041383A patent/MY139476A/en unknown
- 2004-04-15 HR HRP20150163TT patent/HRP20150163T1/hr unknown
- 2004-04-15 BR BRPI0409471A patent/BRPI0409471B8/pt not_active IP Right Cessation
- 2004-04-15 JP JP2006505132A patent/JP4672647B2/ja not_active Expired - Lifetime
- 2004-04-15 EP EP04727557.3A patent/EP1620396B1/en not_active Expired - Lifetime
- 2004-04-15 TW TW093110566A patent/TWI359135B/zh not_active IP Right Cessation
- 2004-04-15 SI SI200432220T patent/SI1620396T1/sl unknown
-
2005
- 2005-09-15 IL IL170887A patent/IL170887A/en active IP Right Grant
- 2005-10-12 EC EC2005006093A patent/ECSP056093A/es unknown
- 2005-10-19 MA MA28559A patent/MA27765A1/fr unknown
- 2005-11-03 CO CO05112189A patent/CO5700735A2/es not_active Application Discontinuation
- 2005-11-07 NO NO20055226A patent/NO333251B1/no not_active IP Right Cessation
- 2005-11-10 IS IS8122A patent/IS2979B/is unknown
-
2008
- 2008-05-22 AU AU2008202278A patent/AU2008202278A1/en not_active Abandoned
-
2015
- 2015-02-18 CY CY20151100168T patent/CY1116008T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0409471A (pt) | processo para a preparação de 2-cianopirrolidinas n-substituìdas | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| TW200635585A (en) | Monocyclic substituted methanones | |
| HRP20050663A2 (en) | Malonamide derivatives as gamma-secretase inhibitors | |
| BR0114986A (pt) | Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. | |
| EA200970149A1 (ru) | Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии | |
| EA200970171A1 (ru) | Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
| TNSN08414A1 (en) | Terphenyl derivatives for treatment of alzheimer's disease | |
| BRPI0406500A (pt) | processo farmacêutico e compostos preparados pelo mesmo | |
| BRPI0619894B8 (pt) | composto de amina e composição farmacêutica | |
| ATE377000T1 (de) | 5-ht1f agonisten | |
| MY129831A (en) | Process for preparing aripiprazole | |
| DE602006008962D1 (de) | Verfahren zur herstellung von valsartan | |
| CY1107937T1 (el) | Προφαρμακα σε συνδετες υποδοχεα nmda | |
| AR043037A1 (es) | Benzo [1,2,5] tiadiazoles y su uso farmaceutico | |
| NO20081151L (no) | Derivater av 5-pyridinyl-1-azabicklo[3.2.1]oktan, fremgangsmate derav og anvendelse av de samme i terapi | |
| BRPI0518998A2 (pt) | âmega-feniloctanamidas | |
| BR0312773A (pt) | Método para produzir um composto altamente puro | |
| BR0110642A (pt) | Processo para preparação de sais de sulfonilbenzoilguanidìnio | |
| TW200612943A (en) | 4-trifluoromethoxyphenoxybenzene-4'-sulfonic acids, process for their preparation and use in medicaments | |
| BRPI0410565A (pt) | processo para sìntese de compostos heterocìclicos | |
| BRPI0408653A (pt) | sìntese de ésteres de ácido 2-clorometil-6-metilbenzóico | |
| DE50206142D1 (de) | Verfahren zur herstellung von 1,3-disubstituierten 2-nitroguanidinen | |
| BRPI0413724A (pt) | processo para sìntese de 3-(3-flúor-4-hidroxifenil)-7-hidroxinaftonitrila | |
| BRPI0409644A (pt) | processo para a preparação de nicotinaldeìdos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2015, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/04/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 20A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |